RxDoctor Payments Data

Bryan Gray, DO

Dermatology · Lima, OHNPI 1831514025

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Lilly USA, LLC at 59.3% of the total. 2025 is the largest year on record at $38,692, more than ten times the $766 reported in 2019. Among dermatology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$55,486in general payments, 2019–2025

Across 904 payments — averaging $61.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$33K
  • Sun Pharmaceutical Industries Inc.$6K
  • AbbVie$3K
  • Incyte Corporation$3K
  • Johnson & Johnson$2K
  • Sanofi$882
  • plus $7K from 36 others

What the payments were for

  • Consulting fees$5,2009%
  • Speaking & faculty fees$31,61357%
  • Travel & lodging$2,2944%
  • Food & beverage$15,53528%
  • Education$8442%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,486 in reported general payments places this provider in the 90th percentile of 460 dermatology providers in Ohio.

See all dermatology providers in Ohio

Medicare billing

Part B allowed, 2024
$3,509,913
Medicare patients
1,632
Services billed
36,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab39$516,736
Dupixent PenDupilumab98$422,745
Skyrizi PenRisankizumab-Rzaa13$255,135
RinvoqUpadacitinib28$233,837
Taltz AutoinjectorIxekizumab18$115,774
Clobetasol Propionate169$8,495
Fluorouracil78$6,666
Acitretin23$6,346
Triamcinolone Acetonide320$3,250
Ketoconazole226$3,040
Doxycycline Hyclate106$2,652
Mupirocin441$2,642
Ammonium Lactate99$2,228
Metronidazole28$2,130
Fluocinonide33$1,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$2,979$233,83728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 460 dermatology providers in Ohio.

Other dermatology in Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →